Omeros Corporation (OMER)
$18.43-2.38%Close
BUYRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 2.57
- P/E (TTM)
- 9.65
- Short % float
- 16.31%
- Days to cover
- 7.0
- SI change
- -8.9%
- 1W
- -1.71%
- 1M
- +7.34%
- vs SPY 1W
- -1.57%
- vs SPY 1M
- +4.83%
Industry peers
FMP comparable companies · ranked by market cap
- RCUSSELLArcus Biosciences, Inc.$3.1BCRISISQ 17$24.41+0.09%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 15$24.63-0.55%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-4.29%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95+2.37%
- NKTRSELLNektar Therapeutics$1.2BCRISISQ 12$41.17-2.72%
- CGEMSELLCullinan Therapeutics, Inc.$954MCRISISQ 1$15.53-3.26%
- CRVSSELLCorvus Pharmaceuticals, Inc.$885MCRISISQ 12$10.52-0.32%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on OMER?
- LOPJLB’s latest quantitative signal on Omeros Corporation (OMER) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is OMER in?
- Omeros Corporation (OMER) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Omeros Corporation (OMER) do?
- Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system…